Active, not recruitingPhase 3NCT05101187

Olorofim Aspergillus Infection Study

Studying Aspergillosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: F2G Biotech GmbH
Principal Investigator: Johan Maertens, MD
UZ Leuven
Intervention: Olorofim(drug)
Enrollment: 225 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2026

Study locations (30)

University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
University of California Davis Health System, Sacramento, California, United States
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California, United States
University of Florida, Gainesville, Florida, United States
Augusta University, Augusta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
The Johns Hopkins Hospital, Baltimore, Maryland, United States
NIH Clinical Center ,NIAID,NIH, Bethesda, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Washington University School of Medicine, St Louis, Missouri, United States
+15 more locations on ClinicalTrials.gov

Collaborators

Iqvia Pty Ltd · Shionogi

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05101187 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis →

← Back to all trials